A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

Project Details

StatusFinished
Effective start/end date25/04/17 → 24/04/21

Funding

  • Boehringer Ingelheim International GmbH: $19,257.80

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research